Patent · US Active

Substituted sodium 1H-pyrazol-5-olate

US8653074B2 · kind B2 · utility

1Cited by

5References

9Claims

0Family size

Assignee

Bayer Intellectual Property GmbH · DE

Inventors

Hans-Christian Militzer · Odenthal, DE
Jörg Gries · Haan, DE
Stefan Koep · Ennepetal, DE

Key dates

Filing date	Nov 8, 2011
Grant date	Feb 18, 2014
Priority date	—
Expiry date	Dec 16, 2031

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P43/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present application relates to sodium 1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate, to processes for its preparation, to its use for the treatment and/or prophylaxis of diseases and to its use for the preparation of medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular and haematological diseases and kidney diseases, and for promoting wound healing.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.